Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life-Reference-Cited by-同舟云学术

Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life

Published:2024-05-23 Issue:1 Volume:20 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Hosman Tessa¹,van Heesbeen Roy¹,Bastian Arangassery Rosemary¹,Hu Weihong¹,Comeaux Christy¹,Ligtenberg Nynke¹,van Montfort Bart¹,Callendret Benoît¹,Heijnen Esther¹

Affiliation:

1. Clinical Development and Medical Affairs, Janssen Vaccines & Prevention B.V ., Leiden, The Netherlands

Funder

anssen Infection Disease & Vaccines

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2344970

Reference18 articles.

1. WHO. Respiratory syncytial virus (RSV) disease. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease.

2. Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus

3. Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis

4. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study

5. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study;Vaccine;2024-12